About Donisi Health
Donisi Health is a MedTech company with a focus on aiding patients with Congestive Heart Failure (CHF) and other chronic cardiopulmonary diseases. The company offers FDA-cleared, contact-free technology that remotely detects signs of pulmonary congestion, supporting early detection of changes in lung fluid content and helping to prevent unnecessary rehospitalization. Donisi Health primarily serves the healthcare industry. It was founded in 2015 and is based in Tel Aviv, Israel.
Donisi Health's Products & Differentiators
Gili Pro BioSensor
Donisi’s first-generation tabletop device for the detection of multiparameter health detection.
Expert Collections containing Donisi Health
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Donisi Health is included in 4 Expert Collections, including Conference Exhibitors.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Companies developing, offering, or using electronic and telecommunication technologies to facilitate the delivery of health & wellness services from a distance. *Columns updated as regularly as possible; priority given to companies with the most and/or most recent funding.
Precision Medicine Tech Market Map
This CB Insights Tech Market Map highlights 160 precision medicine companies that are addressing 9 distinct technology priorities that pharmaceutical companies and healthcare providers face.
Latest Donisi Health News
Oct 19, 2022
Read full article ·2 min read MedTech Startup Focused on Home Monitoring for Patients with Congestive Heart Failure and Other Chronic Diseases Wins the 2021 ICI Pitch Competition and $200,000 Award TEL AVIV, Israel, Dec. 8, 2021 /PRNewswire/ -- Donisi Health (Donisi) prevailed in this year's ICI Innovation Competition – the premier international conference for innovations in cardiovascular intervention. Competing against startups from all over the world in front of a panel of twenty industry expert judges, Donisi took home First Place honors and a $200,000 award for their innovative solution to enable in-home monitoring for key health bio-markers for patients with Congestive Heart Failure (CHF) and other chronic diseases. Donisi Health Takes Home First Place in the Prestigious Innovations in Cardiovascular Intervention Competition (PRNewsfoto/ContinUse Biometrics, dba Donisi Health, Donis) Donisi has the only clinically validated, contact-free technology that can detect signs of pulmonary congestion remotely, supporting the continuum of care for remote patient monitoring and hospital-at-home services. Based upon FDA-cleared technology and backed by 11 granted patents, Donisi's AI-based system detects and analyzes multiple health bio-indicators simultaneously - without the need to remove clothing or connect the patient to wires or patches - delivering clinically meaningful insights and notifications of changes in key health indicators. "We are honored to be recognized by this prestigious institution, and are grateful to the ICI team for highlighting our breakthrough technology's potential to meaningfully improve cardiovascular health," said Donisi's CEO Yair Brosh. "We are focused on developing solutions for chronic patients at home, with a goal to reduce readmission rates for CHF patients.." In the United States, CHF is the #1 cause of readmission among Medicare (65+) patients, with at least 20% of patients readmitted within 30 days and 50% within 6 months. With an average cost of readmissions in the tens of thousands of dollars per patient, direct medical costs for CHF in the US total over $21.7 billion annually. Story continues "This doesn't need to be the case," said Donisi's new Chief Medical Officer, Dr. Shaddy Hassan. "It is known that when heart failure exacerbations are detected early, and healthcare teams intervene while patients are still at home before their condition worsens, many of these costly readmissions can be avoided, resulting in significant cost reduction and improved quality of life." For more information please contact: Hannah Carimi
Donisi Health Frequently Asked Questions (FAQ)
When was Donisi Health founded?
Donisi Health was founded in 2015.
Where is Donisi Health's headquarters?
Donisi Health's headquarters is located at HaBarzel 32b, Tel Aviv.
What is Donisi Health's latest funding round?
Donisi Health's latest funding round is Biz Plan Competition.
How much did Donisi Health raise?
Donisi Health raised a total of $200K.
Who are the investors of Donisi Health?
Investors of Donisi Health include ICI Innovation Competition.
Who are Donisi Health's competitors?
Competitors of Donisi Health include Acorai and 4 more.
What products does Donisi Health offer?
Donisi Health's products include Gili Pro BioSensor and 2 more.
Compare Donisi Health to Competitors
Biofourmis discovers, develops, and delivers clinically-validated, software-based therapeutics. The company produces Biovital, a personalized, artificial intelligence (AI) powered health analytics platform to predict clinical exacerbation. It was founded in 2015 and is based in Boston, Massachusetts.
Solianis Monitoring operates in the web hosting and online services sector, providing a range of internet hosting solutions. The company offers flexible web hosting packages, email services, and tools for creating professional websites without the need for programming knowledge. Its services cater to individuals and businesses looking to establish an online presence. It was founded in 2005 and is based in Switzerland.
CareLigo provides medical technology services. It offers clinically validated remote care solutions and care portal digital care sessions for heart failure patients. It was founded in 2012 and is based in Akersberga, Sweden.
Sensydia provides a point-of-care hemodynamic measurement platform and devices. The company offers proprietary sensor technology and machine learning to guide critical patient management decisions in heart failure, sepsis, pulmonary hypertension, and other critical diseases. Sensydia was founded in 2015 and is based in Los Angeles, California.
Endotronix develops an integrated platform to provide reimbursable health management tools for patients suffering from chronic heart failure. The company's solution includes a cloud-based disease management data system and outpatient hemodynamic management with a wireless pulmonary artery sensor for early detection of worsening heart failure.
Vectorious Medical Technologies is a company focused on the development of medical technology, specifically within the cardiovascular health sector. The company's main product is an in-heart microcomputer, which provides early detection of heart failure by directly measuring left atrial pressure. This technology is primarily aimed at the healthcare industry, particularly those dealing with cardiovascular health. It was founded in 2011 and is based in Tel Aviv, Israel.